Skip to content

The effect of the intensive treatment of basal insulin combined with alpha-glucosidase inhibitor in newly diagnosed type 2 diabetes.

The effect of the intensive treatment of basal insulin combined with alpha-glucosidase inhibitor in newly diagnosed type 2 diabetes.

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-IPB-15006364
Enrollment
Unknown
Registered
2015-05-05
Start date
2015-04-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

Intervention group:Basal insulin combined with alpha-glucosidase inhibitor

Sponsors

Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Outpatients were diagnosed type 2 diabetes and had not recieved previous antihyperglycaemic therapy.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes or secondary diabetes; 2. Patients who recieved previous antihyperglycaemic therapy; 3. History of acute diabetic complications, history of trauma and history of surgery within the past month; 4. With severe chronic diabetes complications(such as diabetic nephropathy, diabetic retinopathy); 5. Patients with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system primary serious diseases; 6. Malignant tumor, pregnant women and those with poor general condition; 7. With a history of abdominal operation or intestinal obstruction, long-term medication affecting intestinal motility and chronic intestinal diseases; 8. Participating in other clinical trials; 9. Alcohol or psychoactive substance abusers and addicts; 10. According to the judgment of researchers, it will reduce the possibility to participate the study or make the participating more complex, for example, change the work or living environment frequently.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;2 hour postprandial blood glucose;Glycolated hemoglobin;Oral glucose tolerance test;

Secondary

MeasureTime frame
Weight;Waist hip ratio;Blood lipid;routine urine;

Countries

China

Contacts

Public ContactZhongming Wu
wuzhongming@tijmu.edu.cn+86 13672093136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026